RU2017113007A3 - - Google Patents

Download PDF

Info

Publication number
RU2017113007A3
RU2017113007A3 RU2017113007A RU2017113007A RU2017113007A3 RU 2017113007 A3 RU2017113007 A3 RU 2017113007A3 RU 2017113007 A RU2017113007 A RU 2017113007A RU 2017113007 A RU2017113007 A RU 2017113007A RU 2017113007 A3 RU2017113007 A3 RU 2017113007A3
Authority
RU
Russia
Application number
RU2017113007A
Other versions
RU2684396C2 (ru
RU2017113007A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017113007A publication Critical patent/RU2017113007A/ru
Publication of RU2017113007A3 publication Critical patent/RU2017113007A3/ru
Application granted granted Critical
Publication of RU2684396C2 publication Critical patent/RU2684396C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
RU2017113007A 2014-10-29 2015-10-27 Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS) RU2684396C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462069915P 2014-10-29 2014-10-29
US62/069,915 2014-10-29
PCT/KR2015/011386 WO2016068580A2 (en) 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)

Publications (3)

Publication Number Publication Date
RU2017113007A RU2017113007A (ru) 2018-11-29
RU2017113007A3 true RU2017113007A3 (ru) 2018-11-29
RU2684396C2 RU2684396C2 (ru) 2019-04-09

Family

ID=55851908

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017113007A RU2684396C2 (ru) 2014-10-29 2015-10-27 Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS)

Country Status (13)

Country Link
US (1) US9834550B2 (ru)
EP (1) EP3212647B1 (ru)
JP (1) JP6505222B2 (ru)
KR (1) KR101978899B1 (ru)
CN (1) CN107001358A (ru)
AU (1) AU2015340215B2 (ru)
BR (1) BR112017008312A2 (ru)
CA (1) CA2962917C (ru)
MX (1) MX2017005346A (ru)
NZ (1) NZ730475A (ru)
RU (1) RU2684396C2 (ru)
SG (1) SG11201702075QA (ru)
WO (1) WO2016068580A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10450300B2 (en) * 2015-10-08 2019-10-22 Suzhou Yunxuan Yiyao Keji Youxian Gongsi Wnt signaling pathway inhibitors and therapeutic applications thereof
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
IL310023A (en) 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
WO2020011086A1 (zh) * 2018-07-13 2020-01-16 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途
AU2021214350C1 (en) 2020-01-31 2023-12-14 Kumiai Chemical Industry Co., Ltd. 3-alkoxybenzamide derivative, and pest control agent
EP4126847A1 (en) 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2022207752A1 (en) * 2021-03-31 2022-10-06 Duke Street Bio Limited Pharmaceutical compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
BR0214414A (pt) * 2001-11-26 2004-09-14 Dsm Ip Assets Bv Processo para recuperar caprolactama
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
US8969363B2 (en) * 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ706857A (en) * 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
HUE033380T2 (en) 2012-10-02 2017-11-28 Gilead Sciences Inc Inhibitors of histone demethylases
WO2014055634A1 (en) 2012-10-02 2014-04-10 Yale University Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
ES2644828T3 (es) 2013-03-15 2017-11-30 Quanticel Pharmaceuticals Inc Inhibidores de histona desmetilasa
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
CN103694255A (zh) * 2014-01-09 2014-04-02 华中师范大学 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑

Also Published As

Publication number Publication date
RU2684396C2 (ru) 2019-04-09
EP3212647B1 (en) 2019-04-03
US20160122343A1 (en) 2016-05-05
RU2017113007A (ru) 2018-11-29
EP3212647A4 (en) 2018-04-18
MX2017005346A (es) 2017-08-02
CN107001358A (zh) 2017-08-01
CA2962917C (en) 2019-04-30
NZ730475A (en) 2018-09-28
AU2015340215B2 (en) 2018-11-15
KR101978899B1 (ko) 2019-05-15
JP6505222B2 (ja) 2019-04-24
AU2015340215A1 (en) 2017-04-13
WO2016068580A2 (en) 2016-05-06
CA2962917A1 (en) 2016-05-06
US9834550B2 (en) 2017-12-05
BR112017008312A2 (pt) 2017-12-19
EP3212647A2 (en) 2017-09-06
SG11201702075QA (en) 2017-04-27
WO2016068580A3 (en) 2016-08-18
KR20170072943A (ko) 2017-06-27
JP2017533215A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
BR112016017659A2 (ru)
BR112016021515A2 (ru)
BR112016017381A2 (ru)
BR112016015518A2 (ru)
BR112016019980A2 (ru)
BR112016018865A2 (ru)
BR112016020457A2 (ru)
BR112016021334A2 (ru)
BR112016020898A2 (ru)
BR112016016467A2 (ru)
BR112016022191A2 (ru)
RU2017113007A3 (ru)
BR112016025671A2 (ru)
BR112016027312A2 (ru)
BR112016021888A2 (ru)
BR112016030707A2 (ru)
BR102014025482A8 (ru)
JP1531023S (ru)
BR122020017677A2 (ru)
JP1520788S (ru)
BR112016018429A2 (ru)
CN302707389S (ru)
CN302757461S (ru)
CN302701125S (ru)
CN302697317S (ru)